Plasma–Nanomedicine Synergistic Therapy for Brain Diseases: Current Status, Applications, and Challenges
Open Access
- 26 January 2026
- journal article
- review article
- Published by MDPI AG in Antioxidants
- Vol. 15 (2) , 166
Abstract
Brain diseases such as ischaemic stroke, Alzheimer’s disease (AD), and glioma were characterized by high mortality and disability rate, and oxidative stress remains a major obstacle in treatment. Plasma–nanomedicine synergistic treatment technology provides a very attractive treatment strategy based on complementarity. This technology integrates cold atmospheric plasma (CAP) with nanomedicine. CAP produces active substances that regulate oxidative stress, while nanomedicine is specially designed for targeted delivery, controlled release, and microenvironmentally responsive activation of therapeutic agents. This integration generates new therapeutic functions and significantly improves the overall therapeutic effect. Despite the broad prospects of this emerging technology, researchers in the fields of medicine, physics, or pharmacy have not yet paid much attention to it. To fill this research gap, this review describes the physicochemical properties and biological effects of CAP and summarizes the latest advances in plasma nanomedicine strategies in the field of brain disease intervention, and reviews the four major nanomedical categories—metal-based, inorganic non-metallic, polymer-based and hydrogel systems—and their clinical applications in the treatment of brain tumors, strokes and neurodegenerative diseases in conjunction with CAP. Finally, we highlight a number of key challenges—limited resources of special CAP equipment, incomplete understanding of the mechanism, obstacles to transformation application—and put forward the future research direction to promote the development of accurate, safe, and clinical transformation value plasma–nanomedicine therapy for brain diseases.Keywords
Funding Information
- National Natural Science Foundation of China (82271572)
- National Natural Science Foundation of China (82230044)
- National Key Research and Development Program of China (2025YFC2511201)
This publication has 103 references indexed in Scilit:
- Specifically Breaking Through the Injured Blood‐Brain Barrier With Tannic Acid‐Based Nanomedicine for Ischemic Stroke Ischemia Reperfusion TreatmentExploration, 2025
- Rapid discovery and optimization of novel brain shuttles and shuttle‐enabled anti‐amyloid therapeutics using multiplexed in vivo biologics designAlzheimer's & Dementia, 2024
- Discovery of half‐curcumin‐based chemiluminescence probes and their applications in detecting quasi‐stable oxidized proteinsAlzheimer's & Dementia, 2024
- Tau‐targeting nanoparticles for treatment of Alzheimer's diseaseExploration, 2024
- Plasma‐Derived Nanoclusters for Site‐Specific Multimodality Photo/Magnetic Thrombus TheranosticsAdvanced Healthcare Materials, 2023
- Advanced strategies to evade the mononuclear phagocyte system clearance of nanomaterialsExploration, 2023
- Neuroprotective Treatments for Ischemic Stroke: Opportunities for NanotechnologyAdvanced Functional Materials, 2022
- Effect of Cold Atmospheric Plasma Therapy vs Standard Therapy Placebo on Wound Healing in Patients With Diabetic Foot UlcersJAMA Network Open, 2020
- Atmospheric pressure plasma treatments protect neural cells from ischemic stroke‐relevant injuries by targeting mitochondriaPlasma Processes and Polymers, 2020
- In Vivo Processing of Ceria Nanoparticles inside Liver: Impact on Free‐Radical Scavenging Activity and Oxidative StressChempluschem, 2014